Tetra Bio-Pharma Inc. (TBP:CSE) Enters into Distribution and Supply Agreement with Engen Medical Corporation
Tetra Bio-Pharma Inc. Enters into Distribution and Supply Agreement with Engen Medical Corporation
– Momentum Public Relations –
Press Release: February 6, 2017
Agro-Tek Inc. (“Agro-Tek”) a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announced today it has entered into an five (5) year exclusive Supply and Distribution agreement with Engen Medical Corporation (“Engen”) for the Canadian distribution of its Munchies B Gone gum. In exchange for a payment of $28,000 on signing the agreement and a minimum purchase commitment of $1,580,000 over five years, Agro-Tek will have exclusive sales and distribution rights in Canada. Engen will be responsible for all manufacturing and regulatory aspects.
Approximately $500 million of chewing gum was sold in Canada last year and $3.5 billion was sold in the United States. Sugar-free gum is expected to show the greatest growth within the sector in both Canada and the United States over the next few years. (Source: The Globe and Mail published Wednesday, February 04, 2015).
The worldwide chewing gum market grew by about 20 per cent between 2009 and 2014, reaching $24.7-billion in 2014. And it is projected to grow another 32 per cent to $32.5 billion by 2019. (Source: The EuroMonitor).
“Tetra is excited to be teaming up with Engen to bring Munchies B Gone to the Canadian market. This distribution agreement launches the first line of revenue generating products for Agro-Tek,” said Andre Rancourt, CEO of Tetra. Agro-Tek is currently in negotiations with multiple distributors servicing the over 3,000 cannabis lifestyle and retail stores that exist in Canada and cater to the Cannabis consumer.
“We are extremely excited about working with Agro-Tek to launch our Munchies B Gone gum into the Canadian market,” said Paul Epner, Co-Founder and Managing Director of Engen.
About Engen Medical Corporation. Engen, a privately held United States corporation, owns the global patent and intellectual property rights to several chewing gum products, including Munchies B Gone gum catering to the cannabis and holistic herbal consumer.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
King’s Bay (KBG:tsxv) Acquires 100 Interest in Three Additional Cobalt Properties in Quebec
King’s Bay Acquires 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Interest in Three Additional Cobalt Properties in Quebec
Historic samples yielding values up to 2.6{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Ni, 1.8{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Cu and 1.06{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Co
– Momentum Public Relations –
Press Release: February 6, 2017
King’s Bay Gold Corporation (TSX.V: KBG), (FSE: KGB1), operating as “King’s Bay”, a mining exploration and development company based in Vancouver, is pleased to announce the 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} acquisition of three cobalt bearing properties in Quebec.
Kevin Bottomley states “The price for cobalt continues to rise and thus we feel having a greater portfolio of cobalt bearing projects provides the best value for our shareholders. Quebec has a strong history of successful mining ventures and King’s Bay is pleased to build on the exploration work that was done by Falconbridge Ltd. in early 2000.”
1. Ninuk Lake Cobalt Property
The Ninuk Lake Project is located approximately 175 kilometers northeast of Umiujag, Quebec and consists of 19 mineral claims encompassing 2164 acres. A deep-sea port is located 125 kilometers from the property.
In 2001 Falconbridge Ltd. completed an exploration program consisting of surface sampling, mapping and electromagnetics. Surface sampling of massive sulfide in outcrop yielded anomalous values of up to 2.6{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Ni, 1.8{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Cu, and 0.27{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Co. Mapping of the area exposed several lenticular ultramafic bodies containing pods massive sulfide. A small-scale electromagnetics program yielded several subsurface conductors in the area. Due to several other discoveries that year, the exploration work by Falconbridge Ltd. was not followed up. The compilation of these results encourages further work to be completed on the property.
Regional Geology– The area is Neoarchean in age and located within the superior province with ultramafic-felsic rocks including granodiorite, tonalite, paragneiss, amphibolite, peridotite, pyroxenite, and gabbronorite. Structurally the area of interest is bounded to the east and west by two regional fault systems
2. Broadback River Cobalt Property
The Broadback River Project is located only 24 kilometers northwest of the Nuinsco Discovery zone and consists of 9 mineral claims encompassing 1035 acres. The property can be easily accessed by the James Bay Road north from Matagami and then by logging roads to the property approximately 75 kilometers inland.
In 1985 a magnetic and electromagnetics survey was flown by the Quebec Ministry of Natural Resources that uncovered several large conductors. In 1999-2000 Falconbridge Ltd. took 152 samples and uncovered semi massive sulphide assaying 0.7{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Ni, 0.3 Cu, and 0.09{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} Co but only drill tested the northwestern portion of the property. All southeastern conductors remain untested.
Regional Geology- The area is Archean in age and dominated by intrusive gabbro, which cuts felsic and mafic volcanics and iron formation of the Frotet-Evans Belt.
3. Roberge Cobalt Property
The Roberge Project is located 2.1 kilometers southeast of Chesterville, Quebec and consists of 3 mineral claims encompassing 443 acres. The property is easily assessable by a paved road, which runs through the property. Soil sampling on the property revealed several anomalous sediment samples assaying up to 1.06{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} cobalt. The work was done by the Quebec Government through a regional soil sampling program and can be found in open report DV 84-16.
Exploration Program
King’s Bay has commenced data compilation along with the initiation of an exploration plan consisting of sampling, local-scale mapping and channel sampling which will be completed this spring to reconfirm historical results.
NI 43‐101 Disclosure
Edward Lyons, P. Geo. supervised the preparation of the technical information in this news release and is a qualified person as defined by National Instrument 43‐101.
About King’s Bay
King’s Bay is focused on the exploration of cobalt and other high‐tech metals in North America. The company believes in this emerging fast‐growth sector and will continue to seek out and evaluate properties that show promise for development. King’s Bay Gold Corp is operating as “King’s Bay.”
- Published in King's Bay, Mining, News Home
Cruz Capital grants options to buy three million shares
Cruz Capital grants options to buy three million shares
Mr. James Nelson reports
CRUZ GRANTS STOCK OPTIONS
Cruz Capital Corp. has granted, pursuant to its 10-per-cent rolling stock option plan, three million incentive stock options to directors, officers and consultants at an exercise price of 20 cents per share for a term of four months. These shares are not subject to a hold period.
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Cruz Cobalt, Mining, News Home
Stakeholder Alignment – A Predictor of Success in Green Technologies
Stakeholder Alignment – A Predictor of Success in Green Technologies
Pundits and prognosticators should take notice. The evidence points to an emerging reality that is leading the so-called green technology revolution. Futurists and visionaries may be looking for some incredible and revolutionary breakthrough, but a variety of compelling new technologies are already being commercialized.
Green energy technologies are those that either harness power from renewable, sustainable sources or aim to reduce adverse human impact on the environment. For new sources of energy to be widely implemented, investors, technologists, and policymakers must understand their potential impact and the path to market that will ensure their commercial viability. Many new technologies can be successful if they are deployed according to sound business principles.
While some allegedly green technologies are struggling to gain traction with businesses and consumers, others are quietly changing the world and addressing the need for responsible and functional solutions to complex environmental challenges.
So, where are these technologies, who is behind them and why are they quietly seizing momentum in the marketplace? The answers are remarkably simple. Like most advances over the course of history, they are conceptually simple, relatively inexpensive and only modestly disruptive.
The automobile is an example of change that occurred at the onset of the 20th century. It harnessed an older technology of propulsion but applied it in a different format. With the advent of mass production, overall costs per unit were reduced and the technology became widely affordable. Additionally, it did not usher in an entirely new mode of transport. It only eliminated the need for an animal to provide propulsion and made travel a modest amount more rapid and marginally more reliable.
As we head towards the conclusion of the first 20 years of the 21st century, the keen observer will be able to identify technologies that have moved from ideas to commercial reality and are quickly going mainstream. Several may be below the radar at the moment, but they won’t stay there for long.
Green technologies are not immune from the ordinary laws that govern business success. The idea that some “better mouse trap” will sell itself is as false as it is comedic. The business success comes from being well capitalized, having a superior value proposition and ensuring that business leadership is equipped and motivated to execute against objectives in a disciplined and systematic manner. If the product or service is ground breaking, wonderful. Who doesn’t love something that is groundbreaking? But does it deliver what I want?
This raises the important principle of stakeholder alignment. If a new technology can align the interests of several disparate interested parties in an industry sector, it has a particularly good chance for success. Stakeholder alignment creates unstoppable momentum for green technologies. In most instances, being more eco-friendly, while desirable, isn’t the primary motivator of change. However, when a number of constituencies all experience a simultaneous benefit that is both measurable and meaningful, change proceeds and the adoption of the new technology is perceived as essential rather than optional.
An example of stakeholder alignment is a fast-growing Hawaiian enterprise called Elevate Structure. It was launched in 2012 by a team of residential engineers in with a dream to develop profitable spaces for living by building eco-friendly structures. The portable spaces are elevated above ground and, therefore, utilize 6-20 times more usable space while minimizing the overall footprint on the ground. This uses less than desirable land, gives consumers the flexibility to expand or relocate their green homes and provides municipalities with new incremental tax revenues without adding infrastructure.
Another good example of stakeholder alignment is International Wastewater Systems of Vancouver, Canada, http://www.sewageheatrecovery.com. Employing a simple idea and proprietary technology, IWS has pioneered the concept of turning the energy contained in warm waste water into heat that is processed, reclaimed and reused. With an ingenious idea and a scalable solution, the company is poised for success internationally as its solutions are increasingly in demand. The success of the endeavour isn’t exclusively due to the green technology. It is because the technology has been able to address diverse needs among a broad group that includes energy providers, builders and building owners. The company’s solutions, green technology and ease of implementation presents and unassailable value proposition to anyone who wants to reduce the heating and cooling costs of buildings. The eco-story is largely secondary. The “green argument” involves saving large amounts of money!
Investors that are considering taking a position in new green technologies are advised to look beyond the excitement of a product or process. A company’s financial state is always a consideration. What have they sold and what projects are well underway? As important as these fundamentals are, it is also critical to examine the “alignment factor” of the product or service to properly evaluate the scope of its potential.
- Published in Blog, Energy, Green Technology, International Wastewater Systems
The 2017 Standards of Medical Care in Diabetes: an update from the ADA
The 2017 Standards of Medical Care in Diabetes: an update from the ADA
The American Diabetes Association (ADA) has released the 2017 update to its Standards of Medical Care in Diabetes (Standards).1 The document is reviewed each year by a multidisciplinary committee of experts in diabetes care, which examines relevant research that informs the revisions.
“The most recent update to the ADA Standards of Medical Care addresses many new and important issues regarding the management of patients with diabetes,” said Kevin M. Pantalone, DO, staff endocrinologist and director of clinical research at the Cleveland Clinic Foundation. The 2017 Standards contain the usual guidelines pertaining to type 2 diabetes prevention and the diagnosis and treatment of type 1, type 2, and gestational diabetes. Additionally, Dr Pantalone identified several of the most notable updates.
One recommendation suggests considering metabolic surgery for patients with obesity and uncontrolled type 2 diabetes who have a body mass index (BMI) as low as 30 kg/m2 (27.5 kg/m2for Asian Americans). This update is based on a growing body of research showing that metabolic surgery — previously referred to as bariatric surgery — leads to improved glycemic control and reduced cardiovascular disease (CVD) risk in this patient population compared with other medical and lifestyle interventions.2 The committee also noted that the safety of metabolic surgery has significantly improved in the past 2 decades: Related mortality rates are 0.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} to 0.5{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}, which are similar to the rates associated with hysterectomy or cholecystectomy.2
Another update recommends considering 2 specific glucose-lowering therapies (glucagon-like peptide-1 [GLP-1] receptor agonists or sodium-glucose cotransporter-2 [SGLT2] inhibitors) for high-risk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the EMPA-REG OUTCOME (ClinicalTrials.gov identifier: NCT01131676) and LEADER (ClinicalTrials.gov identifier: NCT01179048) trials.
The EMPA-REG OUTCOME study examined the effects of the SGLT2 inhibitor empagliflozin vs placebo and usual care in high-risk patients with CVD who have diabetes.3 The findings show that the drug led to a 14{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} reduction in the composite outcome of myocardial infarction (MI) and stroke, and a 38{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} reduction in CV death over a median follow-up period of 3.1 years.3 As a result, the US Food and Drug Administration (FDA) added a new indication for empagliflozin to reduce CV mortality risk in adults with type 2 diabetes and heart disease.4 In a similar manner, results from the LEADER trial showed that the GLP-1 receptor agonist liraglutide resulted in fewer MI, stroke, or CV deaths compared with placebo (13{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} vs 14.9{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}) over a median follow-up period of 3.8 years.5
The committee also sought to further define hypoglycemia. The update indicates that a level of lower than 54 mg/dL (3.0 mmol/L) should be considered serious, clinically important hypoglycemia, even in the absence of symptoms. It is recommended that values below this level be reported in clinical trials and practice. Previous recommendations defined hypoglycemia in hospitalized patients as blood glucose levels <70 mg/dL (3.9 mmol/L) and severe hypoglycemia as levels <40 mg/dL (2.2 mmol/L). Severe hypoglycemia is now defined as “that associated with severe cognitive impairment regardless of blood glucose level,” and a level ≤70 mg/dL “is considered an alert value and may be used as a threshold for further titration of insulin regimens,” according to the Standards.
“Also, and perhaps most important, is the Standards’ acknowledgment and addressing of the socioeconomic aspects of diabetes management: medication cost and self-management support,” Dr Pantalone added. “These areas had been inadequately addressed by earlier versions of the guideline.”
The new version includes 2 detailed tables that provide the estimated monthly cost of various glucose-lowering medications, and the section on reducing disparities in diabetes care states that community health workers, peers, and lay leaders can facilitate the delivery of diabetes self-management education (DSME) and support services. “Strong social support leads to improved clinical outcomes, a reduction in psychosocial issues, and adoption of healthier lifestyles,” the committee noted.
Other notable additions include recommendations pertaining to screening and mental health referrals for patients with depression, anxiety, diabetes distress, eating disorders, and other psychological issues; greater emphasis on assessing comorbidities in patients with diabetes, and an expanded list of such comorbidities, including mental disorders as well as autoimmune disease and HIV; a new physical activity recommendation to break up sedentary behavior every 30 minutes to reduce associated behaviors illuminated by recent research; and increased options for both glucose management and hypertension treatment.
“The ADA has done a fantastic job of remaining on top of the new advances in diabetes management, incorporating new findings and recommendations into the guidelines in a timely manner, but doing so only after a thorough and vigorous review of the recently published medical literature,” said Dr Pantalone.
References
- American Diabetes Association. Standards of medical care in diabetes–2017. Diabetes Care. 2017;40(Suppl. 1):S6-S10.
- Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861-77.
- Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117-2128.
- FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [news release]. Silver Spring, MD: FDA; December 2, 2016. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed January 18, 2017.
- Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
- Published in Bio technology, Blog, Life Sciences, Sirona Biochem
Namaste (N:CSE) Approved to Retail Marley Natural Brand Accessories
Namaste Approved to Retail Marley Natural Brand Accessories
– Momentum Public Relations –
Press Release: February 2, 2017
Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ) is pleased to announce that it has been approved by Little Bay, Inc. (“Little Bay”) (a subsidiary of Privateer Holdings Inc.) as a retailer of the Marley Natural™ (“Marley Natural”) accessories product line in the United States. Marley Natural is the official cannabis brand of Bob Marley, one of the most iconic names in the cannabis industry. The brand is deeply rooted in the ideas and legacy of Bob Marley and celebrates nature, justice and the positive potential of the herb. The terms of resale will be governed by a retail agreement between Namaste and Little Bay.
The collection is made from American Black Walnut and accented by heat resistant hand-blown glass that ensures durability, convenient maintenance, and a comfortable hand-held feel. Namaste’s in-house merchandising team has identified the Marley Natural brand as an ideal collection for specific growth markets. Namaste will market the Marley Natural products to its customer list of over 250,000 individuals and through its e-commerce brands including Namaste Vapes, Everyonedoesit and VaporSeller.
Management Commentary
Sean Dollinger, President and CEO of Namaste, comments: “We are very pleased to carry the Marley Natural brand, the official cannabis brand of Bob Marley. We also pleased to have entered our first commercial arrangement with one of the Privateer Holdings companies, a leader in the cannabis industry, and look forward to further developing a relationship as both our companies expand.”
About Marley Natural
Marley Natural™ is dedicated to creating uniquely designed accessories and offers an elevated line of smoking products for discerning herb connoisseurs. Balancing intuitive form, with subtle Jamaican-inspired accents, the line caters to a personalized and very sensory approach to the classic ritual of smoking. Marley Natural accessories may only be used with legal smoking herbs and may not be used with tobacco products.
About Namaste Technologies Inc.
Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 e-commerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.
On behalf of the Board of Directors
Sean Dollinger, Chief Executive Officer
Further information on the company and its products can be accessed through the links below:
- Published in Namaste Technologies, News Home
Tetra Bio-Pharma Inc. (TBP:CSE) Receives Notice of Authorization from Health Canada
Tetra Bio-Pharma Inc. Receives Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product
– Momentum Public Relations –
Press Release: February 1, 2017
PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for PhytoPain Topical Gel Relief (“PPTGR”), being developed as a locally administered therapeutic for the treatment of Chemotherapy-Induced Neuropathic Pain (“CIPN”).
CIPN is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily stopping it. In other patients the symptoms of CIPN may last for months or years after the cancer therapy has stopped. CIPN symptoms are managed using the same analgesics used to manage other types of neuropathic pain. Some of these analgesics also cause intolerable side effects in patients. The use of a topical counterirritant may help reduce the symptoms of CIPN and avoid exposing some patients to oral neuropathic pain analgesics.
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
Namaste (N:CSE) Commences Distribution Through eBay
Namaste Commences Distribution Through eBay
– Momentum Public Relations –
Press Release: February 01, 2017
Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (CSE:N.CN) (FRANKFURT:M5BQ) is pleased to announce that it has commenced distribution through eBay Inc. (“eBay”), a global commerce leader that connects millions of buyers and sellers around the world. eBay has formally approved Namaste’s marketing templates and products have been listed for sale. As one of a select number of companies in the vaporizers and accessories industry to be permitted to distribute through eBay’s marketplace, Namaste will list its products under the recently launched vaporizers and e-cigarettes category.
Namaste will be required to keep sufficient product inventory on hand in the anticipation of increased demand through eBay’s marketplace and ensure adherence to all applicable category policies. Namaste is currently carrying over $1.5 million of inventory to meet demand from its growing customer base.
Management Commentary
Sean Dollinger, President and CEO of Namaste, comments: “We are very pleased to be one of a select number of vape companies to start distribution through eBay, one of the largest online marketplaces in the world. Going forward, we will continue to add additional items to this marketplace and see this platform an excellent means to expand the Namaste brand.”
About eBay Inc.
eBay Inc. is a global commerce leader that includes Marketplace, StubHub and Classifieds platforms. Collectively, the platforms connect millions of buyers and sellers around the world. The technologies and services that power these platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it virtually anytime and anywhere. The Marketplace platforms include the online marketplace located at www.ebay.com, its localized counterparts and the eBay mobile apps; which are among the world’s largest and most vibrant marketplaces for discovering great value and unique selection.
About Namaste Technologies Inc.
Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 e-commerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.
On behalf of the Board of Directors
Sean Dollinger, Chief Executive Officer
Further information on the company and its products can be accessed through the link below:
- Published in Medical Marijuana, Namaste Technologies, News Home